Pharmexa presents data from the HER-2 Protein AutoVac™ breast cancer trial at a Conference in Hamburg Summary: Pharmexa is presenting data from the first clinical trial in USA with the HER-2 Protein AutoVac™ vaccine at the 4th European Breast Cancer Conference (EBCC) in Hamburg, Germany.
The data presented show that the vaccine is well tolerated and safe and that it induces significant HER-2 specific antibodies in breast cancer patients. Based on these results, Pharmexa plans the continued development of the vaccine through additional clinical investigations in the second half of 2004.
Pharmexa is presenting the full results from the clinical phase I trial with the HER-2 Protein AutoVac™ vaccine conducted at the Ireland Cancer Center in Cleveland, Ohio and the Magee Women’s Hospital in Pittsburgh, Pennsylvania. The vaccine is designed to induce antibody responses against the HER-2 protein that is over expressed in many human cancers, including some cancers of the breast.
Breast cancer patients received 4 injections of the vaccine formulated in a standard aluminium adjuvant. HER-2 specific antibody responses were detected in 6 out of 10 patients in the trial. The first responses were detected after only 2 injections and were significantly boosted following subsequent immunisations. Additional responders were also detected after the 3rd and 4th immunisations.